Skip to main content

Table 3 Biochemical urinary safety parameters

From: Choline-stabilized orthosilicic acid supplementation as an adjunct to Calcium/Vitamin D3 stimulates markers of bone formation in osteopenic females: a randomized, placebo-controlled trial

 

Normal range

Placebo (n = 37)

ch-OSA

     

3 mg Si (n = 33)

6 mg Si (n = 33)

12 mg Si (n = 33)

 

LL

UL

Baseline

T12

Baseline

T12

Baseline

T12

Baseline

T12

Urine analysis*

          

Glucose*

  

0

0

0

1

0

0

0

0

Proteins*

  

2

0

0

0

1

0

1

2

Ketons*

  

0

0

0

0

0

0

2

0

Bilirubine*

  

0

0

0

0

0

0

0

0

Urobilinogene*

  

0

0

0

0

0

0

0

0

Blood*

  

1

2

0

0

0

0

0

2

Nitrite*

  

0

0

0

1

1

0

1

0

Leucocyte esterase*

  

16

19

9

12

8

6

13

18

pH

4,6

8

6,49 ± 0,90

6,28 ± 0,71

6,08 ± 0,89

5,83 ± 0,51

6,20 ± 0,76

6,36 ± 0,84

6,00 ± 0,65

5,98 ± 0,66

Urea/creatinine

13,5

32

24,15 ± 7,16

26,41 ± 7,81

24,03 ± 8,22

24,24 ± 9,48

24,69 ± 6,01

24,76 ± 8,32

23,58 ± 7,08

22,13 ± 7,34

Creatinine (g/L)

0,60

1,80

0,63 ± 0,36

0,63 ± 0,41

0,63 ± 0,39

0,77 ± 0,45 (a)

0,50 ± 0,29

0,63 ± 0,42

0,66 ± 0,62

0,76 ± 0,63

Uric acid/creatinine

0,23

0,68

0,49 ± 0,20

0,47 ± 0,20

0,45 ± 0,19

0,39 ± 0,21

0,50 ± 0,21

0,43 ± 0,18

0,48 ± 0,25

0,42 ± 0,21

Sodium/creatinine (mmol/g)

90

200

166,09 ± 68,78

168,15 ± 99,21

178,37 ± 109,89

165,28 ± 157,62

171,38 ± 111,23

162,55 ± 100,52

144,02 ± 85,53

118,99 ± 85,45

Potassium/creatinine (mmol/g)

22,7

113,6

78,17 ± 40,39

66,96 ± 33,02

67,20 ± 43,67

54,49 ± 27,96

73,13 ± 46,85

66,05 ± 33,25

66,44 ± 28,54

57,37 ± 27,89

Calcium/creatinine (mg/g)

45

273

169,18 ± 85,86

239,76 ± 130,58 (a)

195,61 ± 114,65

268,46 ± 160,38 (a)

240,19 ± 136,88

261,81 ± 135,76

198,32 ± 101,83

190,55 ± 113,90

Phosphorus/creatinine

0,36

1,18

0,96 ± 0,31

0,90 ± 0,29

0,96 ± 0,32

0,82 ± 0,31(a)

0,93 ± 0,29

0,81 ± 0,36

0,99 ± 0,26

0,77 ± 0,26 (a)

Magnesium/creatinine (mg/g)

64

109

117,32 ± 51,29

125,79 ± 44,99

118,73 ± 57,22

119,54 ± 50,40

131,46 ± 46,21

125,54 ± 54,17

132,52 ± 65,26

110,76 ± 69,66

  1. Baseline urinary biochemical safety parameters and after 12 months treatment with placebo (Ca/vit D) and three different ch-OSA doses (Si + Ca/vit D; Si: 3, 6, 12 mg/day), mean ± SD. LL: Lower limit; UL: Upper limit; * number of patients with parameter present in urine; (a) p < 0.05 versus baseline (two-tailed t-test).
Back to article page

BMC Musculoskeletal Disorders

ISSN: 1471-2474

Contact us